Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KWZY-9a: sourced facts only. name: "SAR analysis revealed that compound 9a exhibited promising PARP1 inhibitory activity and demonstrated significant anti-proliferative effects in both breast cancer MDA-MB-231 and ovarian cancer A2780 cells." [PMID:41192280]; target: "SAR analysis revealed that compound 9a exhibited promising PARP1 inhibitory activity and demonstrated significant anti-proliferative effects in both breast cancer MDA-MB-231 and ovarian cancer A2780 cells." [PMID:41192280]; developer: "Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China." [PMID:41192280]; stage: "SAR analysis revealed that compound 9a exhibited promising PARP1 inhibitory activity and demonstrated significant anti-proliferative effects in both breast cancer MDA-MB-231 and ovarian cancer A2780 cells." [PMID:41192280]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KWZY-9a.